Wego

What Wego does

Shandong Wego Intervention Medical Technology Co., Ltd. (山东威高介入医疗科技有限公司) is a second-tier industrial group under diversified Chinese conglomerate Wego Group Co., Ltd. (威高集团有限公司, founded 1988), specializing in the manufacture of interventional medical device consumables across cardiovascular, neuro-intervention, peripheral vascular, non-vascular, and intensive care applications. The subsidiary was reorganized/renamed in 2022 from the prior "Wego Heart Internal Consumables Group" and operates approximately 400-600 employees with manufacturing and R&D sites in Weihai (HQ), Laiwu, Shenzhen, Tianjin, Shanghai, Suzhou, and Beijing, plus US engineering operations in Irvine, California (NeuroVasc Technologies) and Minnesota (Zurich Medical).

The company's product portfolio is built on a five-platform R&D architecture covering stent/occluder/coil, catheter access, balloon, active devices, and absorbable materials. Flagship technology is the Xinsorb (心祥) bioresorbable sirolimus-eluting coronary stent — China's first domestically developed PLLA-based fully bioresorbable stent, approved by the NMPA in March 2020 after a 12-year R&D program supported by five national-level research projects. Other notable proprietary products include the HELIOS Ti-O coated cobalt-chromium drug-eluting stent (Shenzhen Kinrhyly subsidiary), the NeuroVasc Envi-SR mechanical thrombectomy retriever with eccentric multi-segment architecture (CE marked, NMPA Innovative Device Green Channel entry February 2025), Visee detachable coils for intracranial aneurysm embolization, and a bilateral-channel controllable-release vena cava filter.

Wego Intervention commercializes via a hybrid B2B go-to-market model: a 170+ office direct sales force plus a 240+ authorized distributor network covering 7,000+ Chinese hospitals across 30+ provinces, complemented by exports to 100+ countries and selective OEM partnerships (e.g., India Rivarp). Revenue is generated primarily through hardware sales of interventional consumables (stents, coils, catheters, filters, guidewires, balloons), with pricing negotiated through direct sales and distribution channels and subject to China's national volume-based procurement (带量采购) regime. The company completed its first external equity financing — a ~RMB 1 billion (~US$155M) Series A led by Xinjin Capital with CCB International, Haifu Yangtze River Growth Fund, and China-Belgium Direct Equity Investment Fund — on October 28-29, 2021, and was the only Chinese medical device company on the 2020 China Top 500 Enterprises list (#375).

Name

Wego

Legal name

山东威高介入医疗科技有限公司

Website

https://weigao-intervention.com

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

251–500 employees

Short description

Wego Intervention is a Chinese interventional medical device company manufacturing cardiovascular, neurological, and peripheral vascular consumables — including China's first domestically developed bioresorbable coronary stent — sold through a 170-office direct sales force, 240+ distributors, and exports to 100+ countries.

Ownership category

akta.pro rank

Product category

Interventional Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (33911), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

akta.pro secondary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Interventional medical devices
• Cardiovascular stents
• Bioresorbable scaffolds
• Neurovascular devices
• Peripheral vascular devices

Headquarters

HQ city

Nanshan

HQ country

China

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. Medical Device Product Sales (Cardiovascular, Neuro, Peripheral Intervention Consumables): Primary revenue from sale of self-developed interventional medical devices and consumables (stents, occluders, coils, guidewires, catheters, balloons, filters, endoluminal stents) via direct sales and distributor channels. Commercial pricing policies applied to products including Xinsorb bioresorbable stent; trade-in/installer conferences used to recruit distributors and launch new SKUs.
2. OEM / White-label Manufacturing for International Partners: OEM/white-label production partnerships (e.g., discussions with India-based Rivarp on neuro-intervention OEM) enable revenue via contract manufacturing without direct brand-led distribution in target overseas markets.
3. Parent Wego Group Diversified Revenue (Construction, Real Estate, Finance): Wego Group (威高集团, parent) generates diversified revenue beyond medical devices: real estate/construction (威高建工产业集团), financial holdings (威高金融控股集团, including Weihai Blue Ocean Bank), and commercial complexes (e.g., Wego Shopping Mall). Group reported ~6 million sqm footprint across 80+ subsidiaries.

Pricing tiers

Go-to-market motion5 records

Distribution channels5 records

Marketing channels8 records

Core offering

Shandong Wego Intervention Medical Technology develops, manufactures, and sells interventional medical devices and consumables across five therapeutic areas: cardiac intervention (bioresorbable and drug-eluting coronary stents, occluders, electrophysiology catheters), neuro-intervention (mechanical thrombectomy retrievers, detachable coils, microcatheters), peripheral intervention (vena cava filters, peripheral coils, balloon guide catheters, long sheaths), non-vascular intervention (esophageal, biliary, urethral stents), and intensive care (pressure transducers, central venous catheters). Products are sold through a hybrid of direct sales (170+ offices), 240+ distributors, international export to 100+ countries, and OEM/white-label partnerships with key hospital customers including tertiary academic centers.

Product overview

No substantive product/service overview content was available in the provided source material.

Differentiator

Problem solved

Functional benefit

Brands

• Xinsorb (心祥): Bioresorbable sirolimus-eluting coronary stent system - flagship product line of bioresorbable stents
• HELIOS (海利欧斯)
• Visee (维心)
• NeuroVasc / Envi™-SR
• 维心捷 (Visee Express)

Products and services

• Xinsorb Bioresorbable Sirolimus-Eluting Coronary Stent System (生物可吸收冠脉雷帕霉素洗脱支架系统) Fully bioresorbable sirolimus-eluting coronary stent system for interventional cardiology treatment of coronary artery disease. Built on proprietary PLLA/PDLLA polymer platform that degrades to water and CO2 within approximately 3 years, enabling 'intervention without implant'. Sold to hospitals performing coronary intervention via direct sales and 240+ distributor network. Pre-approval clinical trial enrolled 1,200+ subjects across 38 hospitals with 0% MACE rate at 180 days and 100% procedural success. NMPA registration No. 国械注准20203130197.
• HELIOS Sirolimus-Eluting Coronary Stent (HELIOS 钛氧镀膜钴铬合金药物洗脱支架) Cobalt-chromium alloy sirolimus-eluting coronary stent with proprietary titanium-oxygen (Ti-O) thin-film coating, supported by 7+ patents and developed under China's National 973 Basic Research Program. Sold to hospitals at approximately 30% below imported equivalents. Produced by Shenzhen Kinrhyly Biotechnology (subsidiary acquired April 2015). NMPA registration No. 国械注准20163131174.
• NeuroVasc Envi-SR Mechanical Thrombectomy Retriever (Envi-SR 机械取栓支架) Nickel-titanium self-expanding mechanical thrombectomy stent retriever with unique eccentric multi-segment open/closed-loop architecture, every segment radiopaque, designed for retrieval within 8 hours of ischemic stroke. Developed by NeuroVasc Technologies Inc., the Wego Intervention US subsidiary in Irvine, California. CE-marked and serving patients in 35+ countries. NMPA Innovative Device Special Review entry February 10, 2025.
• Visee Detachable Coil and Delivery System for Intracranial Aneurysm Embolization (颅内动脉瘤栓塞用电解脱弹簧圈) Platinum-tungsten alloy double-helix detachable coil with electrolytic detachment mechanism and 3D six-face basket framing structure for stable framing. Includes traceable product identification code. Manufactured by Shandong Visee Medical Equipment Co., Ltd. (Wego Intervention subsidiary). Multiple registration certificates across product variants for treatment of intracranial aneurysms via neuro-interventional procedures.
• Pressure Guidewire System / FFR Measurement Device (压力导丝及血流储备分数测量设备) Integrated 0.014-inch pressure guidewire with portable display unit containing microprocessor; uses MEMS piezoresistive sensor for high-sensitivity physiological pressure measurement (FFR - Fractional Flow Reserve). Developed by Zurich Medical Corp. (Minnesota, USA subsidiary). Eliminates the need to purchase and maintain expensive capital equipment by combining the guidewire sensor and display unit in a portable form factor.
• Bilateral Channel Controllable-Release Vena Cava Filter (腔静脉滤器) Second-generation vena cava filter using nickel-titanium super-elastic memory alloy with integrated lantern-shaped net structure; supports bilateral femoral/jugular release with adjustable, controllable positioning and optimized anchor barbs. Manufactured by Shandong Visee Medical. NMPA registration No. 国械注准20243132076.
• Balloon Guide Catheter (球囊导引导管) Ultra-large lumen 0.088"/0.091" balloon guide catheter compatible with multi-device operation during neuro-interventional procedures. Medical silicone balloon with biocompatibility and compliance; full-length braided reinforcement with gradient outer material construction. NMPA registration No. 国械注准20263030087.
• Long Sheath Delivery Catheter (输送导管/长鞘) Full braid-reinforced long sheath with gradient outer material and rounded soft tip; supports 0.072–0.100 inch inner diameters for higher/distal vessel access during peripheral and neurovascular interventional procedures. NMPA registration No. 国械注准20253032480.
• Cardiac Occluder Devices for Congenital Heart Disease (先天性心脏病封堵器系列产品) Series of occluder devices for interventional treatment of congenital heart disease (CHD) including atrial septal defect (ASD), ventricular septal defect (VSD), and patent ductus arteriosus (PDA) closures. Manufactured by Shandong Visee Medical Equipment Co., Ltd. (Wego Intervention subsidiary). Sold to pediatric cardiology and cardiac surgery departments in Chinese hospitals.
• Electrophysiology Catheters – Mapping and RF Ablation (心脏电生理标测电极导管与射频消融导管) Mapping electrode catheters and radiofrequency (RF) ablation catheters for interventional treatment of cardiac electrophysiology disorders (cardiac arrhythmias). Manufactured by Shandong Visee Medical Equipment Co., Ltd. (Wego Intervention subsidiary). Sold to cardiac electrophysiology departments in Chinese hospitals.
• Non-Vascular Stents (Esophageal, Biliary, Urethral) (非血管支架) Stent products for non-vascular interventional treatment of esophageal, biliary, and urethral strictures and obstructions. Manufactured by Shandong Visee Medical Equipment Co., Ltd. (Wego Intervention subsidiary). Sold to gastroenterology, hepatobiliary, and urology departments.
• ICU Critical Care Products (Disposable Pressure Transducers and Central Venous Catheters) (一次性使用血压传感器和中心静脉导管) Disposable pressure transducer sensors and central venous catheters for intensive care unit (ICU) and critical care monitoring. Manufactured by Shandong Visee Medical Equipment Co., Ltd. (Wego Intervention subsidiary). Sold to ICU and anesthesiology departments in Chinese hospitals.

Quantifiable outcome

• Xinsorb achieved 0% MACE rate, 100% immediate procedural success, 100% target lesion success in 30-subject FIM trial at 180 days
• +7 more outcomes

Named customers11 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Twelve partnerships are on record, tiered minor, core and flagship.

• Korea Tourism Organization (KTO / 韩国旅游发展局)minorGTM or Marketing Partner · 24 December 2025Co-marketing campaign with Wego (MENA travel app brand) to attract Middle East / North Africa travelers to Korea. Uses digital content, influencer journeys, and travel tools to promote Korean destinations. NOTE: This partnership pertains to the MENA travel app 'Wego', not Wego Intervention (medical devices) - included for disambiguation only.
• Rivarp (India)coreOEM/ Whitelabel/ Licensing Partner · 27 October 2024OEM cooperation discussions at OCIN 2024 with Rivarp General Manager Chaitanya Lanka and Director M Sunder Rao. Focus on neuro-intervention product series for Indian market; covers regulatory, technical requirements, manufacturing capacity, and market sizing. Represents Wego's international expansion strategy via OEM rather than direct distribution.
• CAS Suzhou Institute of Biomedical Engineering and Technology (中科院苏州生物医学工程技术研究所)coreStrategic or Co-development Partner · 16 April 2022Joint venture established: Wego Guoke Mass Spectrometry Medical Technology (Tianjin) Co., Ltd. (威高国科质谱医疗科技（天津）有限公司). RMB 100 million investment, 3,000 sqm facility in Tianjin Dongli District. Industrializes HTQ-2020 triple quadrupole mass spectrometer with dozens of national invention patents.
• Shandong Hua'an Biotechnology (山东华安生物科技有限公司) - subsidiary developing XinsorbflagshipStrategic or Co-development Partner · 23 August 2018Wholly-owned subsidiary founded February 2008 in Laiwu Industrial Zone (100-mu campus, RMB 197 million total investment). Dedicated R&D unit for bioresorbable polymer stents; led by General Manager Xie Jian with team of medical and polymer experts. Developed Xinsorb (Xinxin) bioresorbable coronary stent.
• Argon Medical Devices / Argon (爱琅) - acquired entity via Wego GroupcoreStrategic or Co-development Partner · 1 January 2018Acquired by Wego Group as part of international expansion strategy under the Belt and Road initiative. Argon operates as an overseas business platform; Wego plans to build it into a pure foreign-investment financing platform with overseas funds, business management system, and R&D system.
• Royal College of Surgeons / Industry Trade Body Affiliations (industry partnerships)minorOthers · 1 January 2018Wego Intervention collaborates with international medical/scientific bodies via conference participation (Germany MEDICA, China-Vietnam, China-Russia, etc.). Cooperative research with international academic institutions including U.S., Germany, Netherlands, Japan, Russia, India, Vietnam, Kyrgyzstan, Kazakhstan, Uzbekistan, Tajikistan, Pakistan spanning 10+ countries.
• Shenzhen Golden Reliable Biotech (深圳市金瑞凯利生物科技有限公司) - acquired subsidiarycoreStrategic or Co-development Partner · 1 April 2015Acquired by Wego Group in April 2015; develops HELIOS Ti-O coated Co-Cr alloy drug-eluting stent (NMPA No. 国械注准20163131174). Founded 2007; expanded facility by 9,500 sqm post-acquisition (3,000 sqm Class 10K cleanroom). Undertakes National Key R&D Program on fully biodegradable polymer stents with vascular tissue repair functionality.
• NeuroVasc Technologies, Inc. (纽瓦斯克公司) - California subsidiaryflagshipStrategic or Co-development Partner · 1 January 2015Wego Intervention subsidiary founded 2015 in Irvine, California. Develops catheter-based neurovascular interventional devices including Envi-SR thrombectomy retriever and microcatheter. Products serve patients in 35+ countries. Provides US R&D presence and direct access to US/European clinical research networks. CE marking obtained; NMPA Innovative Device green channel entry February 2025.
• Zurich Medical Corp. (苏黎世医疗公司) - USA Minnesota subsidiarycoreStrategic or Co-development Partner · 1 January 2013Founded 2013 by President/CEO Gan Jiazhi, COO Cen Jianzu and VP Zhan Jiahua (graduates of MIT, Minnesota, Johns Hopkins, Pepperdine with experience at St. Jude, Medtronic, Boston Scientific). Cardiovascular device innovation, including disposable pressure guidewire system. Co-located with Mayo Clinic, Medtronic, Boston Scientific ecosystem in Minnesota.
• Shandong Visee Medical Equipment Co. (山东维心医疗器械有限公司) - wholly-owned subsidiaryflagshipStrategic or Co-development Partner · 1 January 2009Established 2009 by Wego Group in Weihai High-Tech Zone; operates through four subsidiaries. Core innovation unit for Visee series products including intracranial detachable coils (ViseeJie second generation), vena cava filter, occluders, and other interventional devices. Received 2019 China Industry-University-Research Cooperation Innovation Demonstration Enterprise award.
• Chinese Academy of Sciences - Changchun Institute of Applied Chemistry (中科院长春应用化学研究所)flagshipStrategic or Co-development Partner · 1 January 2008Strategic R&D partnership since 2000 covering bioresorbable polymer materials and stent technology. Co-developed National Engineering Research Center for Medical Implant Devices (2009). Yields Chief Engineer Yin Jinghua (since 2001) and foundational polymer IP for Xinsorb bioresorbable stent and other products.
• Academician Ge Junbo (葛均波) and Fudan University Zhongshan Hospital (复旦大学附属中山医院)flagshipStrategic or Co-development Partner · 1 January 2008Co-development partner for Xinsorb bioresorbable coronary stent program. Ge Junbo performed the First-In-Man (FIM) stent implant surgery; Fudan Zhongshan Hospital provided the pre-clinical research platform (200+ animal experiments) and clinical trial leadership. 5-year follow-up results of first implant published in JACC Cardiovascular Intervention (IF=9.881). Premier Li Keqiang visited Wego Group to monitor Xinsorb progress.

Scale indicators12 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• MicroPort Scientific Corporation: Shanghai-based global medical device company with a substantial cardiovascular intervention business (MicroPort CardioFlow) and NeuroTech division. Directly comparable as a Chinese interventional device specialist across coronary stents, structural heart, and neurovascular devices, serving the same hospital customers with similar GTM model.
• Lepu Medical Technology: Beijing-based leading Chinese medical device company with deep cardiovascular intervention portfolio including drug-eluting stents, occluders, and balloon catheters. Direct competitor in Chinese hospital channels competing for VBP share, with comparable product breadth and distribution depth.
• Penumbra: US-based neurovascular intervention specialist focused on mechanical thrombectomy (Penumbra System, RED, Jet 7) and neurovascular access. Direct comparable to Wego's NeuroVasc Envi-SR retriever in stroke intervention, with strong US clinical footprint that NeuroVasc partially leverages via its California R&D base.
• Asahi Intecc: Japanese specialist in guidewires and microcatheters with major share in coronary, peripheral and neurovascular intervention. Comparable to Wego's catheter access platform and guidewire products; competes in the same clinical use cases particularly in Asian markets.
• JW Medical Systems (JWMS): Qingdao-based Chinese interventional cardiovascular device company acquired by PerkinElmer/Revvity; specializes in drug-eluting coronary stents and balloon catheters. Direct Chinese competitor to Wego's HELIOS and Xinsorb programs with overlapping hospital coverage in Shandong and eastern China.

Broad incumbents

• Medtronic: Global interventional device leader (Medtronic Coronary & Structural Heart, Neurovascular, and Peripheral Vascular). Sets competitive benchmark in stents, thrombectomy (Solitaire), and embolic coils that Wego's Xinsorb and Envi-SR compete against domestically; co-located with Wego's Zurich Medical subsidiary in Minnesota.
• Boston Scientific: Global interventional cardiology and peripheral intervention leader (Promus DES, Eluvia, Ranger DCBs, Watchman). Major imported competitor in Chinese tertiary hospitals and a benchmark for the drug-eluting stent technology Wego's HELIOS and Xinsorb compete with.
• Abbott Vascular: Global coronary stent leader (Xience DES) and pioneer of bioresorbable scaffold technology (Absorb). Direct benchmark for Wego's Xinsorb bioresorbable program and broader structural heart franchise; competitor in China and export markets.
• Terumo Corporation: Japanese global medical device leader with strong coronary intervention franchise (Ultimaster DES) and neurovascular division (MicroVention). Comparable as a diversified interventional device manufacturer with similar product breadth across cardiac, neuro and peripheral categories.
• Stryker Neurovascular: Global neurovascular intervention business (Trevo ProVue retriever, Target coils) and broader neurovascular portfolio. Direct competitive peer for NeuroVasc's Envi-SR retriever and Visee's detachable coils in stroke and aneurysm markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/wego-intervention

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries8 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wego